Navigation Links
ProLindac in Medical News

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

... prolindac Showing High DACH Platinum Activity; Drug Well Tol...s in the Company's clinical development plan for prolindac , a novel DACH platinum drug that has shown t...lts from its Phase 2 monotherapy clinical study of prolindac (TM) in late-stage, heavily pretreated ovarian ...

Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and other product candidates, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the v...

Access Pharmaceuticals Closes Acquisition of MacroChem Corp.

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008

... - prolindac Is Safe And Active in Recurrent Ovarian Cancer; Un... France where the level of anti-cancer activity of prolindac in a heavily-pretreated patient population compare...s in France, demonstrate the potential benefits of prolindac over current platinum therapies: one highlights th...
ProLindac in Medical Technology

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical development strategy for ProLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human cli...

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Company Announces Clinical Trial Plans for 4Q07/1Q08 DALLAS, Aug. 20 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) provided today an update on the clinical development plan of ProLindac, its novel DACH platinum polymer prodrug, and announced plans ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... high dose groups achieved disease stabilization. prolindac was well tolerated overall. DALLAS, March 5 /...ffect of the approved DACH platinum, Eloxatin, and prolindac was well tolerated overall. The maximum tolerated dose of prolindac was established as well as the recommended dose le...

Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea

...lop and commercialize Access' proprietary products prolindac and MuGard for the Republic of Korea. prolindac is Access' novel DACH platinum prodrug currently i...h a double digit royalty upon commercialization of prolindac and MuGard. In addition, in co-operation with Acce...

Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium

... prolindac Demonstrates Sustained and Significant Reductions ...Efficacy Results from an Ongoing Clinical Study of prolindac in Recurrent Ovarian Cancer." prolindac is Access' novel DACH platinum-polymer prodrug, wh...

Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...potential benefits for cancer therapy of combining prolindac with other anticancer agents. "These studies, whi...s year, provide further support to our belief that prolindac has the potential to become an important tool in t...he second poster demonstrates that combinations of prolindac with certain other anticancer compounds produces c...

Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...n San Francisco, CA. An update on Access' ongoing prolindac Phase 2 clinical study will be presented during Po...uesday, October 23, 2007 from 12:30 p.m. PDT. New prolindac preclinical data will appear in two posters presen...toxics, in human colon and ovarian cancer cells." prolindac is a novel DACH platinum prodrug which has been sh...

Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting

...titutes in France. "We are delighted to have two prolindac poster presentations at one of the most prestigiou...re platinum could be administered to patients with prolindac than oxaliplatin before the onset of toxicity. We are currently studying prolindac in a Phase 2 monotherapy trial, treating patients ...
ProLindac in Biological Technology

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

...nd that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue a...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting

... - Data demonstrates that prolindac should provide sustained tumor exposure to platinu...iopolymer" was presented on Monday, April 20. prolindac is Access' novel polymer-based DACH platinum prodr...ovides in vitro and ex-vivo data on the binding of prolindac to blood components, and suggests a mechanistic ra...

Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference

...nd can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob . The replay can be obtained at the same link for 90 days. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals to Present at the Noble Financial Equity Conference

...ommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.

...hese opportunities involve compounds that MacroChem believes show promising late-stage, pre-clinical and early clinical data. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

...he Macau Special Administrative Region and Taiwan. prolindac is Access' novel DACH platinum prodrug currently i...r obtaining the necessary regulatory approvals for prolindac and commercializing the product in the Greater Chi...an of ASK. "We are excited about the potential for prolindac in China, and we are committed to bringing excitin...

Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

....wsw.com/webcast/rrshq13/accp.ob . The replay can be obtained at the same link for up to 90 days after the live presentation. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Announces $2.7 Million New Equity

... Stock will be amended. Closing of the transaction is subject to the fulfillment of customary and usual closing conditions. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...
Other Tags
(Date:1/22/2015)... January 22, 2015 Liberty University has received ... program from the Council for Accreditation of Counseling ... of Liberty’s Center for Counseling & Family Studies , ... of the university’s new School of Behavioral Sciences. Prior to ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 31U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
Other Contents